Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Recent Advances in Treatment of Newly Diagnosed Mantle Cell Lymphoma
Dr. Dreyling Explores Emerging Role of BTK Inhibitors in MCL Treatment
Dr. Visco Discusses RBAC Dose Reduction Strategies for High-Risk MCL
T-Cell Lymphoma Market Report 2025–2032 Highlights Roche, Biocryst, and Bristol-Myers Squibb
NMDP launches awareness campaign using rockstar puppet to promote cell therapy.
Galapagos presents new cell therapy program data at ASH 2025.
Arvinas presents preclinical data for ARV-393 at ASH 2025 meeting.
Gilead and Kite advance blood cancer care with new ASH 2025 data.
Imugene announces webinar on CAR T-naïve lymphomas and ASH presentation.
Abcuro presents interim Phase 1 data on Ulviprubart at ASH 2025.
Genmab highlights new blood cancer treatment advances at ASH 2025 meeting.
Breakthrough discovery brings new hope against aggressive forms of blood cancer.
FDA grants MB-105 priority review for treating relapsed T-cell lymphoma.
B-cell receptor signaling interacts with the microenvironment in mantle cell lymphoma.
New phase 3 trial launches for Pedritac in adult Hodgkin lymphoma.
Dr. Wang discusses CNS bridging radiotherapy safety before CAR T therapy.
Battling cancer taught this Hong Kong sailor to value human connections.
Tafasitamab moves closer to EU approval for relapsed refractory follicular lymphoma.
Outcomes after transitioning from ibrutinib to zanubrutinib in Waldenström macroglobulinemia.
National Canine Lymphoma Month raises vital awareness among dog owners about lymphoma.
Incyte receives positive CHMP opinion for Minjuvi in relapsed follicular lymphoma.
Anaplastic large cell lymphoma of the penis: case report and literature review.
Hodgkin’s lymphoma pipeline 2025 details MOA, ROA, trials, and key companies.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Leukemia & Lymphoma Society Rebrands as Blood Cancer United to Include All Patients
Groundbreaking Treatment Enables Local Nurse to Successfully Overcome Lymphoma Diagnosis
Chemotherapy-Naïve Jejunal Lymphoma Forming a Fistula with the Urinary Bladder
AI Tool Precisely Differentiates Glioblastoma from Primary Central Nervous System Lymphoma
Case Report: Lymphomatosis Cerebri Presenting with Rapid Parkinsonism and Holmes Tremor
Evaluating Effectiveness of Novel Immunotherapy Combinations for Indolent Lymphoma Treatment
Soligenix surges after T-cell lymphoma trial success, sparks trader optimism
Dr. Jingyi Jessica Li appointed Donald and Janet Guthrie Statistics Chair
Non-Hodgkin lymphoma survivor expresses gratitude for participation in clinical trial
Kernal Bio wins $48M ARPA-H grant for affordable CAR-T therapies
95-year-old Racine man shows it’s never too late to fight cancer
HyBryte demonstrates safe and tolerable profile in cutaneous T-cell lymphoma
Low-dose nivolumab presents new therapeutic approach for Hodgkin lymphoma treatment
Renal diffuse large B-cell lymphoma with simultaneous widespread muscle involvement reported
Army veteran is world's first to trial new cancer drug.
Woman shares her inspiring journey while battling Hodgkin's lymphoma.
Rare ALK-positive mesenchymal tumor found in young patient's vagina.
Creating a “watershed moment” for novel therapeutic access in lymphoma.
Evaluating therapeutic options within the lymphoma treatment algorithm.
FDA grants Breakthrough Therapy status to Sonrotoclax for R/R Mantle Cell Lymphoma.
CD20 Bispecifics vs CAR T: Evaluating CRS and ICANS in lymphoma.
Machine learning predicts one-year overall survival in AITL patients.
Woman shares inspiring journey after battling Hodgkin's lymphoma
CAR T-cell Therapy Market may reach US$24 Billion by 2032.
Cutaneous T-Cell Lymphoma 2025 Pipeline: Emerging drugs, market opportunities revealed.
Rare ALK-positive mesenchymal tumor found in young patient's vagina.
Dr. Visco discusses FIL_V-RBAC trial design combining RBAC and Venetoclax.
A father's journey: battling relapse and achieving remission against all odds.
Dr. Dreyling discusses ECHO trial findings on Acalabrutinib plus BR in MCL.
Should patients with Non-Hodgkin Lymphoma receive CAR T therapy or bispecifics?
"Light the Night" returns to support blood cancer patients and families.
FDA approves third-ever treatment specifically for lupus nephritis patients.
Facing cancer’s mortality while making the conscious choice to live fully.
Burkitt Lymphoma therapeutics market projected to grow from 2024 to 2035.
How does CD20 bispecific availability influence treatment decisions in lymphoma patients?
MicroRNA gene mutations, germline or somatic, may predict adult T-cell leukemia/lymphoma risk.
CAR-T Cells for DLBCL as 2nd Line Therapy
High-dimensional proteomics identifies early risk markers across multiple lymphoid cancer subtypes.
Spanish teenager receives lymphoma treatment following hospitalization during Jubilee event.
DelveInsight’s 2025 report highlights promising Hodgkin lymphoma drugs in development.
CAR T-cell therapy market to grow strongly across 7MM by 2034
Embracing life after follicular lymphoma with strength and a new companion.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Immunosuppressive microenvironment drives progression in large B-cell lymphoma post-CAR-T.
Glofitamab shows high response rates in high-risk LBCL patients.
Lymphoma accelerates cellular and tissue aging, pushing them into older states.
In 2023, 20-year-old athlete Evan Moore faced declining performance, lingering hamstring pain, and a
St. Jude survivor transitions from patient to researcher, continuing his race.
Six critical lymphoma symptoms no doctor would ever ignore.
Yescarta approval marks transformative new era in Korean lymphoma treatment.
B-Cell Non-Hodgkin Lymphoma 2025 pipeline: therapies, research, market outlook.
Sylvi Strong: Five-year-old girl courageously shines through cancer’s darkness.
Case report: Non-Hodgkin lymphoma patient with persistent respiratory symptoms post-COVID-19.
Conjunctival MALT lymphoma linked to methotrexate resolves after discontinuation.
Marginal Zone Lymphoma 2025 pipeline: therapies, research insights, market potential.
Lymphoma breakthroughs spotlighted during Blood Cancer Awareness Month for patients.
Fever of unknown origin reveals bone marrow necrosis from DLBCL.
Sexual dysfunction and emotional distress often remain under addressed in lymphoma patients.
Canyon Lake resident pauses firefighting dreams to courageously fight cancer.
Decision support tool empowers patients in managing NHL-related symptoms independently.
DLBCL patients face urgent battle, some tragically dying while awaiting treatment.
Abdulrahman Alhajahjeh: Luspatercept treatment for lower-risk myelodysplastic syndromes/neoplasms pa
Mantle cell lymphoma market expected to reach \$4 billion by 2034.
Exploring single-agent mosunetuzumab’s potential role in frontline marginal zone lymphoma treatment.
AI tool helps 47-year-old farmer stay cancer-free, track progress, prevent relapse.
Arby’s Foundation recognizes and honors Spring Hill cancer patient’s courage.
20-year-old student dies weeks after initially reporting flu-like symptoms.
Emergency responder celebrates remission following diagnosis of rare, life-threatening cancer.
Childhood cancer: shock hits, but parents must stay strong for their child.
Mantle cell lymphoma market to grow 7.6% CAGR, reaching \$4 billion by 2034.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Perfluorobutane CEUS shows starfield sign's value in early cervical lymphoma.
FDA grants priority review to BMS’s Breyanzi for MZL treatment.
Guardians' Nic Enright, lymphoma survivor, secures his first MLB save.
FDA grants priority review to BMS’s Liso-Cel for marginal zone lymphoma.
ALK Non-Small Cell Lung Cancer: Trials, Therapies, Pipeline, and Key Companies
Cancer Survivor Marks Birthday by Covering Hospital Parking Costs for Patients
Vraj Rangrej: Transforming the Future Landscape of Lymphoma Diagnosis and Treatment
Yescarta Cancer Therapy Approved in Korea, Broadening Treatment Choices for Patients
ALK-Positive Advanced NSCLC: Clinical Trials, Therapies, Pipeline, and Key Companies
Clonally Expanded Nodal T-Cell Population Diagnosed as Lymphoma Post-CAR T
Taylor Laroche, 17, Hodgkin Lymphoma Patient from Haverhill, with Mother Jen
Deadly Cancer Diagnosed in Pregnant Woman Following Unusual Morning Sickness Symptoms
Dual-Targeted CAR-T Therapy Demonstrates Promising Results in Relapsed/Refractory DLBCL
CU Anschutz Lymphoma Research Supports Lowering Barriers to CAR T-Cell Treatment
Transcriptomic Profiles of Lymph Nodes Predict Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma
Chinese Oncologist Dies of Cancer at 35, Shares Final Advice
Lymphoma Survivor’s Journey to Becoming Gimli’s Trusted Debt Therapist
\$IBRX: Patients Overcome Rare Lymphoma Without Chemotherapy in CAR-NK Trial
Grade 4 Mucositis in Pediatric Stage IV Burkitt Lymphoma Patient After Methotrexate
Man Ignored Five Symptoms for Years, Later Diagnosed with Stage 4 Cancer
ALCL Therapeutics Market Expected to Reach \$19.9 Billion by 2035
Patient Achieves Remission in Multiple Myeloma and CAR T-Cell Lymphoma
Targeted Therapy Achieves Remission in Patient with CAR-Positive T-Cell Lymphoma

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Dr. Kahl Explores the Changing Role of BTK Inhibitors in MCL
JNJ-4496 Blocks Antigen Escape, Potential Salvage Therapy for R/R LBCL
Latest Advances in Frontline Treatment for Diffuse Large B-Cell Lymphoma
Latest Treatment Advances for Patients With Relapsed/Refractory Follicular Lymphoma
Dr. Danilov Discusses Advancements in Chemotherapy-Free Treatments for MCL
Dr. Evens discusses personalized treatment approaches for Hodgkin lymphoma patients.
PTX is transforming treatment approaches for T-cell lymphoma patients.
Pregnant woman courageously battles stage 4 lymphoma during fifth month.
Case report: Spontaneous regression observed in cranial vault lymphoma.
Study links rare skin cancer to increased lymphoma, infection-related deaths.
Dr. Evens Discusses Prognostic Model for Early-Stage Hodgkin Lymphoma Treatment
Navigating Freedom and Uncertainty During My Cancer Remission Journey Pause
Dr. Kamdar Discusses Post-Liso-Cel Monitoring in MCL and Hematologic Malignancies
Predictive Model Seeks to Personalize Treatment for Hodgkin Lymphoma Patients
UVA Study Finds Mismatched Stem Cell Transplants Safe for Blood Cancers
Dr. Arora Analyzes Temporal Trends in MCL Incidence, 2000–2021
FDA Issues CRL for Glofitamab Plus GemOx in Relapsed DLBCL.
Cutaneous T-cell Lymphoma Market to Grow at 7.1% CAGR.
EHA 2025: Golcadomide demonstrates strong responses in high-risk follicular lymphoma.
Pirtobrutinib shows ORR noninferiority compared to ibrutinib in BTK inhibitor–naive CLL/SLL.
Odronextamab shows lasting high response rates in heavily pretreated R/R follicular lymphoma.
Medication count serves as strong prognostic indicator in lymphoma, CLL, MM.
Dr. Kamdar discusses optimizing patient monitoring after liso-cel treatment in MCL.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Exploring the Rare Lymphoma Landscape
Geriatric assessment shows similar PTCL outcomes in older, younger adults.
Dr. Ghia highlights fixed-duration Ibrutinib-Venetoclax efficacy in CLL/SLL.
Dr. Poh discusses FDA approval of Tafasitamab for follicular lymphoma.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
‍Meeting the Unmet Needs of Patients Treated for Rare Lymphomas
Dr Fenske evaluates auto-HCT’s role in today’s MCL treatment landscape.
Dr. Fenske discusses Auto-HCT's role in the current MCL treatment paradigm.
Dr. Kahl explains why adding Bortezomib to BR induction in MCL.
Dr. Dreyling discusses studying ASCT combined with Ibrutinib and R-CHOP in younger, fit MCL patients
Dr. Kahl Highlights Ongoing Unmet Needs in Mantle Cell Lymphoma Treatment

‍The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
‍Immunotherapy combined with transplantation significantly improves outcomes in relapsed lymphoma.
Multidisciplinary care plays a vital role in bone marrow transplantation.
Dr Dreyling explores BTK inhibitors' growing role in treating MCL.
Advancements in treatment strategies for relapsed/refractory diffuse large B-cell lymphoma.
Nieto discusses AFM13 and progress in treating relapsed/refractory lymphoma.
Identifying obstacles to effective treatment in rare lymphomas.
Overcoming challenges in clinical trial development for lymphoma treatment advancement.
Highlighting current clinical advancements in the treatment of rare lymphomas.

‍The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Latest Advances in Frontline Treatment for Relapsed/Refractory Follicular Lymphoma
Latest Therapeutic Advances and Updates in Follicular Lymphoma Treatment
Latest treatment advancements for mantle cell and marginal zone lymphoma.
Latest updates in standard care and management strategies for Hodgkin lymphoma
Dr. Dreyling explains the rationale behind the TRIANGLE study in MCL.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
LaCasce Discusses How Bispecific Antibodies Are Transforming Lymphoma Treatment.
Dr. van Meerten Discusses Brexu-Cel’s Role in High-Risk MCL.
Dr. Dreyling on ASCT, Ibrutinib, and Rituximab Safety in Young MCL

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Prior CAR T-cell therapy exposure may affect odronextamab benefit in DLBCL.
Durvalumab combination may offer benefits for aggressive T-cell lymphoma subgroups.
Recent Guideline Updates on Frontline Treatment for Chronic Lymphocytic Leukemia
Dr. Fenske discusses omitting ASCT in Mantle Cell Lymphoma after first CR.
Dr. van Meerten discusses Brexu-Cel efficacy and safety in BTK inhibitor–naive R/R MCL.
Dr. Phillips discusses the rationale for evaluating Glofitamab in R/R Mantle Cell Lymphoma.
Acalabrutinib regimen shows combinatorial benefits in mantle cell lymphoma.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org